A Phase 3b, Randomized, Open-Label Assessment of Response to Various Doses of Atomoxetine Hydrochloride in Korean Pediatric Outpatients With Attention-Deficit/Hyperactivity Disorder

Atomoxetine Hydrochloride

Atomoxetine hydrochloride

Atomoxetine hydrochloride

Change From Baseline to Day 42 Endpoint in Attention-Deficit/Hyperactivity Disorder Rating Scale-IV-Parent Version: Investigator Administered and Scored (ADHDRS-IV-Parent:Inv) Total Score

Change From Baseline in Clinical Global Impression-Attention Deficit Hyperactivity Disorder-Severity Scale (CGI-ADHD-S) Score at Days 7, 14, 42, and Last Observation Carried Forward Endpoint

Change From Baseline in Clinical Global Impression-Attention Deficit Hyperactivity Disorder-Improvement Scale (CGI-ADHD-I) Score at Days 7, 14, 42, and Last Observation Carried Forward Endpoint

Adverse Events Leading to Discontinuation

Incidence of Completion of the Columbia Suicide-Severity Rating Scale, Suicide and Self-Harm Summary

Heart Rate Change From Baseline to Day 42 Endpoint

Temperature Change From Baseline to Day 42 Endpoint

Blood Pressure Change From Baseline to Day 42 Endpoint

Weight Change From Baseline to Day 42 Endpoint